PDL BioPharma, Inc.

After striking a licensing deal valued at up to $5bn for a bispecific antibody with US biotech Summit Therapeutics plc in December, Chinese bioventure Akeso Inc. ’s founder, chairwoman and CEO Mich

When bluebird bio announced its plans to split into two separately listed entities, analysts were enthusiastic and social media commentators compared it to a different, recently well-received transa

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Opts Not To Continue Leber Conge

The biopharmaceutical industry has risen to the challenge of the COVID-19 pandemic with dozens of vaccine and therapeutic candidates in development, helping biopharma stocks outperform stocks in many